Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company has shown improved financial performance with reduced operating expenses and net loss. Raised revenue guidance and strategic focus on TearCare's growth potential indicate optimism. Despite some uncertainties in the Q&A, the engagement and expansion plans for TearCare and the MIGS market suggest positive sentiment. The market's reaction is likely to be positive, considering the strategic initiatives and financial improvements.
Key Financial Performance
Third Quarter Revenue $19.9 million, a 1% decrease year-over-year. The decline was attributed to fewer SmartLids sales in the Dry Eye segment as the company focused on achieving reimbursed market access for TearCare procedures.
Surgical Glaucoma Revenue $19.7 million, an increase of 6% year-over-year. Growth was driven by an increase in both ordering accounts and average selling prices, partially offset by lower account utilization.
Dry Eye Revenue $0.2 million, a decrease from $1.5 million year-over-year. The decline was in line with expectations due to fewer SmartLids sales as the company focused on achieving reimbursed market access for TearCare procedures.
Gross Margin 86%, up from 84% year-over-year. Surgical Glaucoma gross margin remained flat at 87%, while Dry Eye gross margin decreased to 38% from 48%, primarily due to higher overhead costs per unit.
Total Operating Expenses $25.1 million, a decrease of 11% year-over-year. The reduction was primarily due to lower stock-based compensation, personnel-related expenses, and research and development expenses.
Adjusted Operating Expenses $19.8 million, a decrease of 17% year-over-year. The reduction was attributed to cost-saving measures, including a reduction in force announced in August.
Net Loss $8.2 million or $0.16 per share, compared to a net loss of $11.1 million or $0.22 per share year-over-year. The improvement was due to reduced operating expenses and restructuring efforts.
Cash and Cash Equivalents $92.4 million at the end of the quarter, with $40 million of debt. Cash used during the quarter was $9.1 million, including $1.5 million of restructuring costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OMNI Surgical Glaucoma technology: Achieved $19.9 million in Q3 revenue, driven by adoption of OMNI technology. Sequential growth of 3% and 6% year-over-year growth in Surgical Glaucoma revenue.
TearCare system: Secured fee schedules for CPT code 0563T in two MAC regions, covering 10.4 million Medicare lives. Payment rate set at $1,142 for participating providers. Early customer interest and reengagement noted.
Market expansion for TearCare: Focused on Medicare-covered regions with 10.4 million lives. Targeting 6,500 eye care providers nationwide, with 200 already using TearCare in these regions.
UnitedHealthcare coverage for OMNI: OMNI included in UnitedHealthcare's expanded coverage for glaucoma surgical treatments, effective October 2025.
Operational efficiencies: Reduced adjusted operating expenses by 17% year-over-year. Achieved $12 million in annualized savings from August reduction in force.
Manufacturing expansion: Plans to expand manufacturing outside China by Q1 2026 to mitigate tariff costs.
Management restructuring: Promoted Ali Bauerlein to COO and Jim Rodberg to CFO to enhance operational and financial leadership.
Strategic priorities: Focused on securing reimbursement for TearCare, accelerating MIGS and Dry Eye commercialization, and advancing clinical and economic evidence for broader adoption.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Costs: The company faces tariff costs on its Surgical Glaucoma products, which have impacted gross margins and cost of goods sold. This creates financial pressure and uncertainty due to the dynamic nature of tariff rates.
Manufacturing Relocation: The company is working to relocate manufacturing outside of China to mitigate tariff exposure. However, this transition involves costs and operational challenges, with new facilities expected to start production in 2026.
Dry Eye Revenue Decline: Revenue from the Dry Eye segment has significantly decreased due to a strategic focus on achieving reimbursed market access for TearCare procedures, which may delay revenue recovery.
Reimbursement Coverage Challenges: While progress has been made in securing reimbursement for TearCare, the company still faces challenges in achieving broader coverage and payment decisions from other MACs and commercial payers.
Reduction in Force: The company implemented a reduction in force in August, which, while reducing costs, may impact operational capacity and employee morale.
Patent Infringement Case: The company has not yet received monetary damages from its successful patent infringement case against Alcon, which could impact financial planning.
Market Competition: The company operates in a competitive market for glaucoma and dry eye treatments, which could impact its ability to capture market share and sustain growth.
Economic Uncertainty: General economic uncertainties could impact customer purchasing behavior and the adoption of the company's products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: Raised to $76 million to $78 million, up from the prior guidance of $72 million to $76 million.
Adjusted Operating Expense Guidance: Lowered to $90 million to $92 million, representing a decrease of 9% to 11% compared to 2024.
Dry Eye Segment Revenue: Expected to be $0.5 million to $1 million for the fourth quarter of 2025.
Surgical Glaucoma Segment Revenue: Fourth quarter revenue growth expected to be in low single digits at the midpoint of the range versus the fourth quarter of 2024.
Manufacturing Expansion: Additional third-party manufacturing locations outside of China expected to begin producing volumes for OMNI Edge and TearCare SmartLids product lines in the first quarter of 2026.
Dry Eye Gross Margin: Expected to expand significantly with higher volumes associated with broader reimbursed market access as commercialization ramps up.
Reduction in Force Savings: Expected to generate approximately $12 million in annualized personnel-related savings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As Chief Operating Officer, what will be your primary focus over the next 6 to 12 months?
A:The primary focus will be on accelerating growth, increasing oversight on day-to-day operations, and driving the successful scale-up of the TearCare franchise. The COO is excited about TearCare's potential as a new category of reimbursed interventional Dry Eye treatment and aims to establish it as a leading treatment in the market.
Q:What are your thoughts on the opportunity created by a competitor repositioning their product in a different sales force?
A:The company has been focusing on selling the benefits of OMNI and winning business as it converts from 2 MIGS to 1 MIGS procedures. They believe they are well-positioned to capture growth in the MIGS market as it returns to growth in 2026, regardless of competitor disruptions.
Q:Can you talk about the initiatives to build engagement and utilization for TearCare?
A:The company has been focused on education, identification, and activation of accounts. They have seen heavy engagement from existing and new accounts, including interest outside the First Coast and Novitas regions. Successful claims have been processed at new payment rates, and they expect substantial ramp-up going into 2026.
Q:What might keep Surgical Glaucoma from growing sequentially in Q4 despite seasonality benefits?
A:There is nothing specific to call out. The company had a strong Q3 and has set prudent and achievable guidance for Q4, which still includes year-over-year growth.
Q:How should we think about TearCare's contribution next year?
A:While specific 2026 guidance is not provided, the company expects significant growth in TearCare due to its small revenue base. TearCare is seen as a large growth driver with recurring revenue potential as patients return for additional treatments.
Q:How should we think about timing on commercial and Medicare Advantage (MA) contracts for TearCare?
A:The company is actively engaging with other MACs and commercial payers. Medicare Advantage plans in the same states as the two MACs are the next easy target due to their requirement to match traditional Medicare plans. Progress is being made, but exact timing is uncertain.
Q:Why have dormant accounts in Surgical Glaucoma started reengaging?
A:Dormant accounts have been reengaging over the past year as clarity on new policies was gained. The company has maintained focus on the MIGS market and has a proven team with long-term relationships with surgeons.
Q:How should we think about the OpEx line in the model next year?
A:The company is not providing 2026 guidance but highlights significant OpEx savings and disciplined expense management. Recent cost reductions were primarily in general and administrative costs, not commercial and sales.
Q:What is the strategy to build more awareness around TearCare therapy?
A:The company plans to expand the customer base and increase payer coverage while targeting 6,500 optometrists and ophthalmologists. They are growing their sales team and focusing on increasing density in states with established fee schedules. TearCare has already been in the market for years, with a good base of awareness and proven effectiveness.
Q:How has the precedent set by Novitas and First Coast influenced conversations with other payers about TearCare?
A:The precedent has strengthened interest from both commercial and MAC payers. Conversations have focused on understanding the clinical and health economic value of TearCare, and the company believes First Coast and Novitas will be the first of many payers to establish coverage.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of accounts in the First Coast and Novitas regions, the exact timing for additional payer coverage, and specific 2026 guidance for TearCare and OpEx. They used general language like 'progressing appropriately' and 'significant growth' without offering concrete data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bauerlein
CFO
COO
Chief Officer
Co Founder
Coast
Dry Eye
Glaucoma segment
MAC
MACs
Novitas
OMNI Edge
Surgical Glaucoma
TearCare treatment
adoption OMNI
area
cause
commercialization
customer engagement
decision TearCare
discipline
disease Surgical
eye disease
eye treatment
fee schedule
market eye
momentum Surgical
overlap glaucoma
potential
promotion
pseudophakic patient
relief
role
schedule TearCare
segment OMNI
selling price
sight
surface
synergy
tech
vision
SGHT Transcript
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-13
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Positive5-7
The company reported strong revenue growth of 15% YoY and improved gross margins, which are positive indicators. The raised revenue guidance for 2026 further supports a positive outlook. Although operating expenses increased, they were driven by strategic investments in R&D and sales, which could foster future growth. The reduction in net loss and improved margins are encouraging, suggesting operational efficiency. Despite the lack of discussion on shareholder returns and operational updates, the overall sentiment leans positive due to strong financial performance and optimistic guidance.
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights several positive developments: raised revenue guidance, reduced operating expenses, and significant market opportunities in the dry eye segment. Despite some cautious guidance and uncertainties in reimbursement and market access, the company's strategic focus and expected cost savings position it for growth. The Q&A session supports this with a generally positive sentiment from analysts, despite some vague responses from management. Overall, the positive aspects outweigh the negative, leading to a positive stock price outlook over the next two weeks.
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Positive11-6
The company has shown improved financial performance with reduced operating expenses and net loss. Raised revenue guidance and strategic focus on TearCare's growth potential indicate optimism. Despite some uncertainties in the Q&A, the engagement and expansion plans for TearCare and the MIGS market suggest positive sentiment. The market's reaction is likely to be positive, considering the strategic initiatives and financial improvements.
SGHT Slides
SGHT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
